Impact of Multiple Doses of BAY63-2521 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Patients With Interstitial Lung Disease (ILD) Associated Pulmonary Hypertension (PH)

NCT ID: NCT00694850

Last Updated: 2025-07-28

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 22 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2008-08-02
• Study Completion Date: 2025-07-03

Brief Summary

The purpose of this study is to assess multiple ascending doses of a new drug (BAY63-2521) given orally, to evaluate if it is safe and can help to improve the well-being, symptoms (e.g. disturbed breathing) and outcome of pulmonary hypertension associated with lung fibrosis. Patients living with pulmonary hypertension associated with interstitial lung disease have a risk of increased number of hospitalisations because of worsening of their condition. Until now there is no approved medication for this disease. The current treatment of pulmonary hypertension associated with interstitial lung disease consists: of oxygen and medical treatment with vasodilators, e.g. so-called Calcium-antagonists. Therefore, there is a need for new drugs in the treatment of pulmonary hypertension associated with interstitial lung disease.

Conditions

Hypertension, Pulmonary

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Arm 1

Group Type: EXPERIMENTAL

Riociguat (Adempas, BAY63-2521).

Intervention Type: DRUG

BAY63-2521 will be up-titrated from 1,0 mg TID to 2,5 mg TID

Interventions

Riociguat (Adempas, BAY63-2521).

BAY63-2521 will be up-titrated from 1,0 mg TID to 2,5 mg TID

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Diagnosis of an interstitial lung disease (usual interstitial pneumonia [UIP], nonspecific interstitial pneumonia [NSIP] or sarcoidosis) with high resolution CT and a total lung capacity (TLC) ≤ 90% or scleroderma associated pulmonary arterial hypertension (PAH) with total lung capacity (TLC) ≤ 80%.
• Interstitial lung disease (ILD) must have been stable for at least 3 months (decrease in forced vital capacity (FVC)< 10% and diffusing capacity of lung for carbon monoxide (DLco) < 15 % in 3 months), i.e. no significant changes in pulmonary function testing and stable medication in terms of ILD (e.g., corticosteroids, immunosuppressants)
• Mean pulmonary vascular resistance (PVR) > 400 dyne sec cm-5 or mean pulmonary arterial pressure (PAP mean) > 30 mmHg
• Pulmonary capillary wedge pressure (PCWP) < 15 mmHg
• Hemodynamic parameters at baseline (PAP, PCWP, cardiac output [CO], systemic mean arterial pressure [SAP])
• High resolution computer tomography (HRCT) (should not be older than 12 months prior start of the study)
• Heart rate > 55 beats per minute (BPM) and < 105 BPM at rest
• Systolic blood pressure (SBP) > 90 mmHg
• World Health Organisation (WHO) functional class II, III and IV
• 6 Minute Walking Test (6MWT) > 100m and < 450 m
• Stable controlled arterial hypertension according to current guidelines
• Women of childbearing potential will be included in the study if the pregnancy test is negative and combination of condoms with a safe and highly effective contraception method (hormonal contraception with implants or combined oral contraceptives, certain intra-uterine devices [IUDs]) is granted.

Exclusion Criteria

• Co-medication:

• Patients pretreated with specific medication for pulmonary arterial hypertension (PAH) like endothelin receptor antagonists, prostaglandins or phosphodiesterase type 5 (PDE 5) blockers are excluded from the trial.
• Requirement for concomitant use of nitrates are contraindicated.
• Pre-existing clinically relevant lung disease other than ILD including.

• Bronchial asthma and Chronic Obstructive Pulmonary Disease (COPD) with a forced expiratory volume in one second (FEV1)/FVC <60% pred., active tuberculosis
• Pulmonary hypertension of another WHO group (I, II, IV and V)
• Severe congenital abnormalities of the lungs, thorax and diaphragm
• Clinical or radiological evidence of a pulmovenoocclusive disease (PVOD)
• Systemic hemodynamics

• Acute or severe chronic left heart failure (ejection fraction (EF) < 50%)
• Severe coronary artery disease (CAD; EF < 50%); CAD patients must be asymptomatic and stable
• Congenital or acquired valvular or myocardial disease if clinically significant apart from tricuspid valvular insufficiency due to pulmonary hypertension
• Pulmonary function

• TLC predicted < 30%
• FEV1 (related to FVC) < 60% predicted
• Blood gases at room air

• Arterial partial carbon dioxide pressure (Pa CO2) > 45 mmHg
• Arterial partial oxygen pressure (Pa O2) < 50 mmHg at O2 supply >/= 4 L/min
• Peripheral organ function

• Moderate or severe hepatic insufficiency (Child-Pugh Class Band C and/or total bilirubin > 2.5 mg/dl (0.043 mmol/L); and/or hepatic transaminases >3 upper limit normal [ULN])
• Moderate or severe renal insufficiency (creatinine > 2 mg/dl) or creatinine clearance according to Cockroft-Gault formula < 35 mL/ min

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Bayer

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Bayer Study Director

Role: STUDY_DIRECTOR

Bayer

Locations

München, Bavaria, Germany

Giessen, Hesse, Germany

Hanover, Lower Saxony, Germany

Homburg, Saarland, Germany

Dresden, Saxony, Germany

Countries

Germany

References

Hoeper MM, Halank M, Wilkens H, Gunther A, Weimann G, Gebert I, Leuchte HH, Behr J. Riociguat for interstitial lung disease and pulmonary hypertension: a pilot trial. Eur Respir J. 2013 Apr;41(4):853-60. doi: 10.1183/09031936.00213911. Epub 2012 Aug 30.

Reference Type: RESULT

PMID: 22936711 (View on PubMed)

Related Links

https://www.fda.gov/drugs/drug-safety-and-availability/drug-safety-communications

Click here and search for drug information provided by the FDA.

https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program

Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.

Other Identifiers

2023-507526-17-00

Identifier Type: OTHER

Identifier Source: secondary_id

2007-003928-37

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

12916

Identifier Type: -

Identifier Source: org_study_id